# **FARES-II Trial**

## A New Standard in Cardiac Surgery Bleeding Management

Octaplex® (4F-PCC) vs. Frozen Plasma (FP):

Evidence from a Landmark Phase III Study

(JAMA 2025 | Multicenter RCT in Canada & US)

#### The Problem: Bleeding in Cardiac Surgery



#### The FARES-II Study: What we did

15% of patients undergoing cardiac surgery experience excessive bleeding

FP has long been the standard for bleeding management, despite safety risks (TRALI, TACO, anaphylaxis) and limited robust data



12 Hospitals: 420 patients


4F-PCC: n = 213**FP**: n = 207


Goal: Compare 4F-PCC vs. FP for hemostatic efficacy and safety



## Key Findings: Octaplex® (4F-PCC) Delivers Superior Results

**4F-PCC** significantly outperforms **FP** across multiple endpoints





### Why does this matter?

The data is clear, now is the time to act.

Octaplex® (4F-PCC) should be the new standard, presenting a significant step for patient blood management:

- Optimize blood product use
- Minimize unnecessary blood transfusions
- **Enhance** patient safety

